Endovision successfully completed a KRW 11.5 billion (USD ~8.6M) Pre-IPO funding round in January 2026, with participation from Quad Ventures, HB Investment, NH Venture Investment, and others. The company is preparing to file for preliminary KOSDAQ listing review in 2026, targeting IPO in H2 2026, led by Korea Investment & Securities and Woori Investment & Securities.
Company Overview (Updated April 2026)
Endovision Co., Ltd. (엔도비전) is a South Korean biomedical platform company headquartered in Daegu, South Korea. Established on April 3, 2013, the company has evolved from a traditional medical device manufacturer into a chitosan-based biomaterial platform enterprise. With proprietary mushroom-derived vegetal chitosan technology, Endovision develops and commercializes hemostatic agents, wound healing materials, spinal/endoscopic surgical devices, joint injections, and skin boosters.
Platform Vision: Rather than focusing on single products, Endovision aims to become a "Biomaterial Platform Company" leveraging chitosan's unique properties (biodegradability, gelation, cross-linking control) that position it as a next-generation biomaterial following PDRN, collagen, and ECM.
Financial Performance & Growth
Revenue Trajectory
2024 Performance:
- Revenue: KRW 12.96 billion (USD ~9.7 million), with operating profit of KRW 190 million
- Assets: KRW 18.08 billion; Equity: KRW 2.87 billion
2025 Performance (Estimated):
- Revenue: Approximately KRW 22 billion (USD ~16.5 million), representing 60-80% year-over-year growth
- Profitability improved significantly due to automation equipment investments
Funding & Investment History
Pre-IPO Round (January 2026):
- Amount: KRW 11.5 billion (oversubscribed, exceeding initial targets)
- Investors: Quad Ventures, HB Investment, NH Venture Investment, Astone Ventures, Comess Investment, Wooshin Venture Investment, Pioneer Investment (Home & Shopping subsidiary)
- Use of Funds: Clinical trials and regulatory approvals for joint injections and skin boosters; expansion of beauty device and cosmetics manufacturing and marketing
Series A (2020): We Ventures, Korea Asset
Additional Investment (March 2026): KRW 1.5 billion from NH Venture Investment, bringing cumulative funding to KRW 13 billion
Core Technology & Products
Chitosan-Based Biomaterials (Platform Technology)
Endovision utilizes mushroom-derived vegetal chitosan (not shellfish-based) as its core material, enabling superior biocompatibility and reduced allergic reactions. Key product categories include:
- Hemostats: Chitosan-based bleeding control agents for surgical and trauma applications
- Wound Care: Advanced wound dressings incorporating antibacterial chitosan hydrogels
- Wound Healing Solutions: Collagen and ECM-based regenerative materials
UBE Spinal & Endoscopic Surgery Systems
World's First UBE (Unilateral Biportal Endoscopy) System:
- Holds domestic and international patents for UBE surgical tools and biportal endoscopic spinal surgery
- Spinuss & Arthross RF Plasma Console: Low-temperature (40-70°C) RF ablation and coagulation system for precise tissue removal
- Compatible Systems: Products compatible with Smith & Nephew, Stryker, Linvatec, and Arthrex systems
- Scope Kits: Patent-protected advanced endoscopes with optimized design for surgical procedures
- Saver System: Dual-mode (foot switch & hand piece) shaver system with real-time data display
Pipeline Products (Clinical/Development)
- Joint Injection: Chitosan-based intra-articular injectAble for osteoarthritis (clinical trials ongoing)
- Skin Booster: Medical aesthetics product line leveraging chitosan technology for dermatological applications
- Beauty Devices: Home-use medical aesthetic devices planned for B2C distribution through partnership with Pioneer Investment (Home & Shopping channel)
Regulatory & Patent Portfolio
Medical Device Approvals
- MFDS (Korean FDA): Over 160 medical device approvals secured over the past decade, ranging from low-risk (Class I) to high-risk (Class IV) implantable devices
- Quality Certifications: ISO 13485, KGMP (Korean Good Manufacturing Practice), CE marking for select products, FDA registration for US market access
Intellectual Property
International Patents:
- US Patent 11,457,909: Sheath device for biportal endoscopic spinal surgery
- US Patent 11,447,001: Guider for spinal operation and cage therefor
- US Patent 11,278,348: High-frequency treatment device for spinal endoscopic surgery
- Additional Patents: Cervical adhesion prevention devices, hemostatic clips, elastic retractors, male urinary incontinence prevention devices, and chitosan-based formulations
Corporate Structure (2026)
Shareholder Structure
- Jeong Min Ho (정민호): 42.85% (CEO & Founder)
- Shin Jin-wan (신진완): 13.11%
- Jeil Pharmaceutical (제일약품): 9.75%
Capital Structure: Total issued shares of 5,234,297 (Common: 3,662,242; Preferred: 1,572,055) with par value of KRW 500 per share (as of February 10, 2026)
Company Profile
Company Name: Endovision Co., Ltd. (주식회사 엔도비전)
Founded: April 3, 2013
Headquarters: 66-26, Dongnae-ro, Dong-gu, Daegu, Republic of Korea (42709)
Representative: Jeong Min Ho (정민호) – CEO & Founder
Employees: 51 (2026)
Business Type: Small-to-Medium Enterprise (SME) / Pre-IPO Company
Industry: Medical Device Manufacturing (Hemostasis, Wound Care, Endoscopic Surgery)
Affiliate: (주)웰바이오랩 (Well Bio Lab)
Website: www.endovision.co.kr
Strategic Directions & 2026 Outlook
IPO Preparation
- Target: KOSDAQ listing in H2 2026
- Lead Underwriters: Korea Investment & Securities and Woori Investment & Securities
- Strategy: Positioning as "Tech-based medical device company with unique chitosan formulation technology" spanning hemostasis, joint injections, and skin boosters
Business Expansion
- B2C Cosmetics: Entering consumer market through partnership with Pioneer Investment (Home & Shopping subsidiary) for beauty devices and cosmeceuticals
- Global Expansion: Current exports to UK, Hungary, and Thailand; expanding to Middle East, Latin America, and Southeast Asia
- Manufacturing Scale-up: Investment in automation equipment to improve profitability and meet growing demand
Market Position
Competitive Landscape
Endovision is recognized as a key player in the global UBE market alongside Karl Storz, Smith & Nephew, Stryker, and Joimax. The company's differentiation lies in:
- Integrated Platform: Only company combining chitosan biomaterials with endoscopic surgical systems
- Cost Competitiveness: "The most competitive price over the world" for RF systems and endoscopic equipment
- OEM Capabilities: Manufacturing for global companies including Zimmer Biomet
Contact Information
Headquarters (Korea)
Address: 66-26, Dongnae-ro, Dong-gu, Daegu, Republic of Korea (42709)
Tel: +82-53-751-1955
Fax: +82-53-751-1964
Email: endosales@endovision.co.kr / info@endovision.co.kr
Website: www.endovision.co.kr
Key Personnel
CEO: Jeong Min Ho (정민호) – Founder and Chief Executive Officer (42.85% shareholder)
Vision: "To become a global bio-technology medical device company used routinely in healthcare worldwide, based on unparalleled chitosan formulation technology"
Keywords: Endovision,엔도비전,chitosan,biomaterial,Pre-IPO,2026 IPO,KOSDAQ,hemostat,wound care,UBE,spinal endoscopy,joint injection,skin booster,medical aesthetics,daegu,jeong min ho,MFDS,quad ventures,NH venture,biportal endoscopy,RF plasma,minimally invasive surgery
